Skip to content

A real-world study to explore clinical characteristics of patients with lung malignant tumors who received surgeries and adjuvant therapies

A multi-centre real-world non-interventional observational study to explore clinical characteristics of patients with lung malignant tumors who received surgeries and surgereis plus adjuvant therapies

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800014701
Enrollment
Unknown
Registered
2018-01-30
Start date
2018-02-01
Completion date
Unknown
Last updated
2018-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung malignant tumors

Interventions

Case series:Surgeries and surgeries plus adjuvant therapies

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: The patients who were enrolled in clinics from 2014 to 2017 and met all the following criteria will be included in the study: 1. Patients >= 18 years; 2. Pathologically diagnosed patients with lung malignant tumors; 3. Patients with surgeries for lung cancer; 4. Patients with complete medical health records and follow-up information (at least one visit).

Exclusion criteria

Exclusion criteria: The patients who met any one of the following criteria will be excluded from the study: 1. Patients who were not performed with surgeries; 2. Pathologically diagnosed patients with benign diseases.

Design outcomes

Primary

MeasureTime frame
Demographic data in patients who received surgeries;

Secondary

MeasureTime frame
Clinical characteristics of patients who received surgereis;Impact factors of patient survivals in patients with tumor size <=2cm;

Countries

China

Contacts

Public ContactLunxu Liu

West China Hospital, Sichuan University

lunxu_liu@aliyun.com+86 13608236600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026